Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

6.200 -0.030 (-0.48%)
Streaming Delayed Price Updated: 12:59 PM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
New Blood Test Reveals Whether Treatment is Working for Brain Cancer Patients
Via Investor Brand Network
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Rami Levin as President and Chief Executive Officer
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Announces CEO Transition
Via ACCESS Newswire
Researchers Use Supplements to Produce Remarkable Outcomes in Brain Cancer Treatment
Via Investor Brand Network
Optimal Treatment Timing Could Boost Cancer Therapy Efficacy
Via Investor Brand Network
Nasal Drops Hold Promise in Fighting Deadly Brain Cancer
Via Investor Brand Network
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Talks Bold Strategy to Treat GBM in BioMedWire Podcast
Via Investor Brand Network
Common Drug for Blood Pressure Could Slow Glioblastoma
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q3 Results and Advances Lead Candidate TPI 287 Toward Phase 2 GBM Study
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Targets Glioblastoma with Innovative Therapies, Addressing One of Oncology’s Greatest Unmet Needs
Via Investor Brand Network
Wegovy, Ozempic Could Reduce Deaths Resulting from Colon Cancer
Via Investor Brand Network
Topics Death
New Implants Defy Necessity of Brain Surgery Against Cancer
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting
Via ACCESS Newswire
Review Shows That Neurocognitive Functioning Declines in Patients with CNS Cancers
Via Investor Brand Network
What Patients Need to Know About the Remission Rate of Glioblastomas
Via Investor Brand Network
Scientists Uncover Possible Driver of ‘Chemo Brain’
Via Investor Brand Network
Virtual Brain Tumors Could Transform How Cancer is Treated
Via Investor Brand Network
New AI Tool Boosts Precision Medicine in Treating CNS Cancers
Via Investor Brand Network
Topics Artificial Intelligence
Scientists Stunned Upon Discovering Glioblastoma Erodes Skull Tissue
Via Investor Brand Network
Scorpion Venom Shows Promise in Brain Tumor Treatment
Via Investor Brand Network
Rogue Rings of DNA Expose Brain Tumor Secrets
Via Investor Brand Network
New Research Suggests Dietary Change Could Improve Glioblastoma Treatment Outcomes
Via Investor Brand Network
NCI Halts Funding for Consortium Conducting Trials on Childhood Brain Cancers
Via Investor Brand Network
News headline image
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Via ACCESS Newswire
Study Finds Link Between Head Injuries and Elevated Brain Cancer Risk
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Drug Development and Market Potential on BioMedWire Podcast
Via Investor Brand Network
Blocking Glioblastoma-Triggered Brain Damage Could Slow the Aggressive Tumor’s Growth
Via Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.